SCYNEXIS Inc
Cerrado
4.77 3.47
Resumen
Variación precio
24h
Mínimo
4.59
Máximo
4.95
Ingresos | -34M -21M |
|---|---|
BPA | -0.418 |
Margen de beneficios | 65.741 |
Empleados | 18 |
EBITDA | -29M -17M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +473.77% upside |
Capitalización Mercado | 53M |
|---|---|
Apertura anterior | 1.3 |
Cierre anterior | 4.77 |
SCYNEXIS Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
SCYNEXIS Inc previsión
Precio Objetivo
By TipRanks
473.77% repunte
Estimación a 12 Meses
Media 28 USD 473.77%
Máximo 32 USD
Mínimo 24 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para SCYNEXIS Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de SCYNEXIS Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
